Daiichi Sankyo Targets 2.3 Trillion Yen in Oncology Revenue by 2030
Event summary
- Daiichi Sankyo unveiled a five-year business plan (FY2026-FY2030) targeting 2.3 trillion yen in oncology revenue by 2030, up from 2.1 trillion yen in FY2025.
- The company aims to become a global top five oncology player by 2035, with 3 trillion yen in revenue and 600 billion yen in operating profit by FY2030.
- Five practice-changing launches are planned in FY2026, including new breast cancer indications for Enhertu® and Datroway®, and a first-ever small cell lung cancer launch with ifinatamab deruxtecan (I-DXd).
- Daiichi Sankyo will leverage its DXd antibody drug conjugate platform and identify new breakthrough generating technologies (BGTs) to accelerate innovation.
The big picture
Daiichi Sankyo's aggressive five-year plan underscores the intensifying competition in the oncology sector, where antibody drug conjugates (ADCs) are becoming a key battleground. The company's focus on rapid market penetration and new indication launches reflects a broader industry trend toward targeted therapies and precision medicine. Success will depend on Daiichi Sankyo's ability to balance innovation with operational efficiency, particularly as it aims to centralize global commercialization activities.
What we're watching
- Execution Risk
- Whether Daiichi Sankyo can sustain the pace of new indication launches across its DXd ADC portfolio, particularly in lung cancer.
- Innovation Pipeline
- How effectively the company identifies and integrates new breakthrough generating technologies (BGTs) to maintain its competitive edge.
- Operational Excellence
- The impact of AI and digital technologies on cost optimization and profit improvement, targeting 200 billion yen by 2030.
Related topics